-
Mashup Score: 6
Program: Oral and Poster Abstracts Type: Oral Session: 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Screening to Vaccines–The Spectrum of Plasma Cell Disorders Hematology Disease Topics & Pathways: Research, clinical trials, Clinical Research, Plasma Cell Disorders, patient-reported outcomes, Diseases, Lymphoid Malignancies, Human Sæmundur Rögnvaldsson, MD, PhD 1,2 *, Sigrun Thorsteinsdottir, MD, PhD 2,3, Jon Oskarsson, MSc 2 *, Elias Eythorsson, MD,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
Program: Oral and Poster Abstracts Type: Oral Session: 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Screening to Vaccines–The Spectrum of Plasma Cell Disorders Hematology Disease Topics & Pathways: Research, clinical trials, Clinical Research, Plasma Cell Disorders, patient-reported outcomes, Diseases, Lymphoid Malignancies, Human Sæmundur Rögnvaldsson, MD, PhD 1,2 *, Sigrun Thorsteinsdottir, MD, PhD 2,3, Jon Oskarsson, MSc 2 *, Elias Eythorsson, MD,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Dr Saemundur Rognvaldsson @SaemundurMD will present data on the early benefits and psychological effects of screening for monoclonal gammopathy of undetermined significance: results of the iStopMM study https://t.co/PcjvDO30R0 @sykristinsson #mmsm #ASH23
-
-
Mashup Score: 9Paper: Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma - 1 year(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Hematology Disease Topics & Pathways: Research, Fundamental Science, Translational Research, genomics, Biological Processes, pathogenesis 1 Sylvester Comprehensive Cancer Center, Myeloma Division, University of Miami, Miami, FL 2 Myeloma Service, Sylvester Comprehensive Cancer Center, University
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Dr Anthony Cirrincione @cirriant will present data revealing novel mechanisms underlying inactivation of tumor suppressor genes on duplicated chromosomes in multiple myeloma https://t.co/BwVelNHC7U @francescomaura4 #mmsm #ASH23
-
-
Mashup Score: 4Paper: Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma - 1 year(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma: Clinical and Epidemiological: Immunological Effects of Sustained Responses in Multiple Myeloma Hematology Disease Topics & Pathways: Research, clinical trials, Translational Research, Plasma Cell Disorders, Clinical Research, Diseases, Lymphoid Malignancies Benjamin Diamond, MD 1, Dickran Kazandjian, MD 2, Marios Papadimitriou, MD 2 *, Bachisio Ziccheddu 3 *, Patrick Blaney, MS 4 *, Monika Chojnacka, B.S. 1, Michael Durante, PhD
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Dr Ben Diamond @BenDiamondMD will present on genomic profiling to interpret the outcomes of early intervention for high-risk smoldering myeloma https://t.co/5UJLpIcBt2 @dikokaz #mmsm #ASH23
-
-
Mashup Score: 5
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Prospective Therapeutic Trials: Smoldering and Newly Diagnosed Myeloma Hematology Disease Topics & Pathways: Research, Biological therapies, Clinical Research, Diseases, Therapies, Lymphoid Malignancies, Study Population, Human Ola Landgren, MD 1, Ajai Chari, MD 2 *, Yael C. Cohen 3 *, Andrew Spencer, MBBS, MD, FRACP, FRCPA 4 *, Peter M. Voorhees, MD 5, Irwindeep Sandhu 6 *, Matthew W. Jenner 7 *, Dean Smith 8 *, Michele Cavo,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
@DrOlaLandgren will present long-term followup data from the daratumumab monotherapy Phase 2 Centaurus study https://t.co/U89zhplp9Q @EagleMyeloma #mmsm #ASH23
-
-
Mashup Score: 17GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed/refractory multiple myeloma | GSK - 1 year(s) ago
Blenrep plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex.
Source: www.gsk.comCategories: General Medicine News, Hem/OncsTweet-
@GSK announces: DREAMM-7 phase 3 trial shows longer PFS for belantamab mafodotin + bortezomib & dexamethasone (BorDex) vs daratumumab + BorDex in relapsed/refractory multiple myeloma #mmsm @IMFmyeloma @theMMRF @HealthtreeMM https://t.co/iR37w0qjmJ
-
-
Mashup Score: 6
Program: Oral and Poster Abstracts Type: Oral Session: 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Screening to Vaccines–The Spectrum of Plasma Cell Disorders Hematology Disease Topics & Pathways: Research, clinical trials, Clinical Research, Plasma Cell Disorders, patient-reported outcomes, Diseases, Lymphoid Malignancies, Human Sæmundur Rögnvaldsson, MD, PhD 1,2 *, Sigrun Thorsteinsdottir, MD, PhD 2,3, Jon Oskarsson, MSc 2 *, Elias Eythorsson, MD,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Dr Saemundur Rognvaldsson @SaemundurMD will present data on the early benefits and psychological effects of screening for monoclonal gammopathy of undetermined significance: results of the iStopMM study https://t.co/PcjvDO30R0 @sykristinsson #mmsm #ASH23
-
-
Mashup Score: 15GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed/refractory multiple myeloma | GSK - 1 year(s) ago
Blenrep plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex.
Source: www.gsk.comCategories: General Medicine News, Hem/OncsTweet-
@GSK announces: DREAMM-7 phase 3 trial shows longer PFS for belantamab mafodotin + bortezomib & dexamethasone (BorDex) vs daratumumab + BorDex in relapsed/refractory multiple myeloma #mmsm @IMFmyeloma @theMMRF @HealthtreeMM https://t.co/iR37w0qjmJ
-
-
Mashup Score: 5
Program: Oral and Poster Abstracts Type: Oral Session: 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: From Light Chain to Fibril–Novel Diagnostics to Treatments for Amyloidosis Hematology Disease Topics & Pathways: Research, adult, epidemiology, assays, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Technology and Procedures, Study Population, Human Thorir Einarsson Long, MD, PhD 1,2 *, Sæmundur Rögnvaldsson, MD, PhD 3 *,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Dr Thorir Einarsson Long will present a revised definition of free light-chains in serum and light-chain monoclonal gammopathy of undetermined significance: results of the iStopMM study https://t.co/1fncmQLeF6 @sykristinsson #mmsm #ASH23
-
-
Mashup Score: 5
Program: Oral and Poster Abstracts Type: Oral Session: 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: From Light Chain to Fibril–Novel Diagnostics to Treatments for Amyloidosis Hematology Disease Topics & Pathways: Research, adult, epidemiology, assays, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Technology and Procedures, Study Population, Human Thorir Einarsson Long, MD, PhD 1,2 *, Sæmundur Rögnvaldsson, MD, PhD 3 *,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Dr Thorir Einarsson Long will present a revised definition of free light-chains in serum and light-chain monoclonal gammopathy of undetermined significance: results of the iStopMM study https://t.co/1fncmQLeF6 @sykristinsson #mmsm #ASH23
-
Dr Saemundur Rognvaldsson @SaemundurMD will present data on the early benefits and psychological effects of screening for monoclonal gammopathy of undetermined significance: results of the iStopMM study https://t.co/PcjvDO30R0 @sykristinsson #mmsm #ASH23